Bristol-Myers Squibb To Buy Biotech ZymoGenetics For $836 Million

Date : 09/07/2010 @ 6:39PM
Source : Dow Jones News
Stock : Zymogenetics (MM) (ZGEN)
Quote : 9.76  0.0 (0.00%) @ 2:05AM

Bristol-Myers Squibb To Buy Biotech ZymoGenetics For $836 Million

Bristol Myers Sqibb (NYSE:BMY)
Historical Stock Chart

5 Years : From Jan 2013 to Jan 2018

Click Here for more Bristol Myers Sqibb Charts.

Bristol-Myers Squibb Co. (BMY) has agreed to pay $9.75 a share in cash for biotechnology company ZymoGenetics Inc. (ZGEN), an 84% premium from the closing price Tuesday.

ZymoGenetics's shares shot up 83% to $9.70 after hours. The stock was down 17% this year as of the close. Bristol-Myers's shares closed at $26.61 and rose 7 cents after hours. That stock was up 5% this year as of the close.

The $836 million deal is expected to reduce Bristol-Myers' earnings by 3 cents a share this year and 7 cents a share next year.

Bristol-Myers plans to begin a cash tender offer on or about Thursday and the offer is expected to close about 30 days later. The acquisition agreement says ZymoGenetics will not solicit competing offers and Bristol-Myers will finance the acquisition from its existing cash resources.

Bristol-Myers Chief Executive Lamberto Andreotti said the acquisition gives the company "full ownership of a promising investigational biologic that strengthens our very diversified Hepatitis C portfolio." The two companies have collaborated on development of pegylated-interferon lambda since January 2009. The product is now in Phase II trials.

Andreotti also noted ZymoGenetics's "proven capabilities with therapeutic proteins and revenue from a marketed specialty surgical biologic."

Among ZymoGenetics's products are Recothrom, a drug for use in surgery to prevent blood clotting; IL-21 protein, which is in Phase II testing as a potential immunotherapy treatment for metastatic melanoma; and six biologic drug candidates for atopic dermatitis.

The company also is in six partnered programs with Merck KGaA (MKGAY, MRK.XE) affiliate EMD Serono Inc. and Novo Nordisk A/S (NVO, NOVO.B.KO).

-By Kathy Shwiff, Dow Jones Newswires; 212-416-2357;

Order free Annual Report for ZymoGenetics, Inc.

Visit or call 1-888-301-0513


Latest ZGEN Messages

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....

No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts

Your Recent History
Gulf Keyst..
FTSE 100
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

NYSE, AMEX, and ASX quotes are delayed by at least 20 minutes.
All other quotes are delayed by at least 15 minutes unless otherwise stated.